Dataset opportunity
Francismedical — 医疗影像数据集机会
Francismedical 持有的中等规模医疗影像数据集,可用于诊断人工智能和计算机视觉。
Score
70
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场 = 2025 年为 18.8 亿美元,复合年增长率为 36.91%。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-11-12
J&J leads Francis Medical investment to fund prostate cancer device
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- ✨Signal
ClinicalTrials.gov:用于前列腺癌的 Vanquish 水蒸气消融术
source ↗
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高(专有)
Accessibility
受限
Legal
公司所有 — GDPR 敏感(PII 审查)
Buyer persona
医疗人工智能与诊断影像公司
Francismedical 持有一个独特的医疗影像数据集,其中包含丰富的 `image_collection`,并结合了 `iot_data` 和 `medical_records`。这种多模态的构成使其特别适合开发和验证高性能诊断人工智能模型。该数据源自正在进行的Vanquish Study临床试验,确保了高质量、结构化且与纵向相关的信息,这对于人工智能开发者来说是一项稀有资产。
该数据集服务于全球医疗影像人工智能市场,该市场在 2025 年的价值为18.8 亿美元,预计将以36.91% 的复合年增长率增长。虽然由于HIPAA和GDPR法规的限制,访问权限需要协商,并且需要IRB 批准才能进行二次使用,但其与正在进行的临床试验的直接联系使其成为一项极其宝贵的资源,证明了旨在引领这一高增长市场的买家的投资价值。⚠ 尽职调查(有价值的数据,可协商访问):医疗数据受 HIPAA 和 GDPR 法规约束;数据与正在进行的临床试验(Vanquish Study)相关;需要进行去标识化和 IRB 批准才能进行二次使用。· 公司:独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Francismedical 拥有一项专有的、多模态的来自前列腺癌临床试验的数据集,独特地结合了纵向的MRI和超声图像以及相应的程序时间序列数据。这对于开发用于治疗监测和结果预测的下一代诊断人工智能的医疗人工智能公司来说,是一项稀有且完整的资产。在预计每年增长近 37% 的医疗影像人工智能市场中,该数据集在高价值肿瘤学领域提供了显著的竞争优势。
See dimension details ↓- Dataset Specificity90
主导的“医疗记录”,医疗保健行业,3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家需求异常高,这得益于医疗影像人工智能市场的爆炸式增长,该市场正以 36.91% 的复合年增长率扩张。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度,独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型,3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有,许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据胃口信号(1 种类型)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高,1 个近期外部信号 — 超出已货币化的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — Francis Medical 是一个理想的目标,因为它是一家预收入的中小型企业,其核心业务是开发和销售医疗设备,并产生有价值的临床试验数据作为副产品,而这些数据目前并未货币化。
- Deep Qualification90
✓ 通过 — Francis Medical 是一家医疗设备公司,其 VAPOR 2 临床试验的数据,包括 MRI 图像,是其研发和监管活动的宝贵副产品,使其成为一个强大的数据持有者候选。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
证据证实存在来自正式临床试验(VAPOR 2)的结构化数据,为人工智能开发者提供了验证前列腺癌诊断模型所需的关键患者和程序背景。
IoT / sensor data
该数据集包括来自医疗设备的专有时间序列数据,捕获了热能输送等程序细节,这对于开发预测治疗效果的人工智能非常有价值。
Image collection
该集合包含高价值的纵向MRI和超声图像,提供了用于训练诊断人工智能以监测治疗区域和预测肿瘤学结果的术前和术后数据。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Francismedical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in medical imaging market = $1.88 billion in 2025, CAGR 36.91% (source: Fortune Business Insights).. Investment score 70.0/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Icedesign — 工业运营数据集机会
View opportunity →交通出行Wascosa — 维护日志数据集机会
View opportunity →金融Auramet — 工业运营数据集机会
View opportunity →